{
  "docId": "019de514-4d4c-7369-a2bf-f736423e3911",
  "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53",
  "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides",
  "authorId": "imara",
  "authorName": "Enliven Therapeutics / Imara",
  "documentKindSlug": "press-release",
  "documentKindLabel": "Press release",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 45,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 35,
  "notes": "The slide highlights a gap in the market for a selective, irreversible TKI for brain metastases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/35",
  "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911",
  "deckJsonHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911.json",
  "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.49,
        "x": 0.48,
        "y": 0.88
      },
      "kind": "callout",
      "text": "No selective, irreversible TKI to meaningfully address brain metastases",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "148e47f3-e16a-429a-a200-489cdcd148c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "AE = Adverse event. ADC = Antibody drug conjugate. AST = Aspartate aminotransferase. ALT = Alanine transaminase. ILD = Interstitial lung disease. NE = Not evaluable. NR = Not reached. ORR = Overall response rate. PFS = Progression free survival. PPE = Palmar-plantar erythrodysesthesia. OS = Overall survival. TKI = Tyrosine kinase inhibitor.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8164fe07-c560-426d-8650-711330186590",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.94,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "table",
      "text": "Comparison table of HER2 breast cancer drugs",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4dc5af71-11a4-45a7-8224-e6bea531abc2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "HER2 Breast Landscape: No Irreversible, Highly Selective TKI Option",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74253415-4142-4e00-9f36-d11a6ac276c6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "e40791dd-815f-42ff-ad2b-bc718f23bb5e",
      "evidence": "Table comparing drug classes and clinical metrics",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}